Oregon Clinical Trials Report — April 2026

For Oregonians considering participation in clinical trials, April 2026 brings both new opportunities and a crucial window to act on studies nearing their enrollment deadlines. Across the state, 66 clinical trials are slated to close within the next 90 days, meaning time is running out to join these important research efforts. This urgency extends to healthy volunteers, with 7 of these rapidly closing studies still actively seeking participants without specific health conditions. If you've been thinking about contributing to medical science, now is the time to explore these options before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of leukemia, asthma, depression, and advanced cancers are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Acute Myeloid Leukemia
• Asthma
• Depression
• Stage IV Lung Cancer AJCC V8
• Glaucoma
• Acute Lymphoblastic Leukemia
• Advanced Breast Cancer
• Acute Undifferentiated Leukemia
• Amyotrophic Lateral Sclerosis (ALS)
• Acute Leukemia

New Horizons in Oregon Research: Obesity, Cancer, and Language Development

This April, Oregon welcomes 9 new clinical trials, offering fresh avenues for participation in groundbreaking medical research. While this number is slightly lower than the 10 new trials that opened in March, the quality and potential impact of these studies remain high, featuring significant Phase 2 and 3 trials from major pharmaceutical companies and leading academic institutions.

Among the most notable new studies are those addressing widespread health challenges and rare conditions alike:

• Novo Nordisk A/S is sponsoring NCT07509307, a Phase 3 study titled "AMAZE 6." This trial investigates a new medicine, NNC0487-0111, for individuals with excess body weight and knee osteoarthritis. Designed for 400 participants, it aims to evaluate how well this weekly injectable treatment helps with weight loss and pain reduction compared to a placebo.
• Incyte Corporation is launching NCT07522073, a Phase 3 study focused on metastatic pancreatic ductal adenocarcinoma (PDAC) with a specific KRAS G12D mutation. This trial will evaluate chemotherapy with or without INCB161734 in 588 previously untreated participants, offering a potential new approach for this challenging cancer.
• For those with a rare inflammatory condition affecting hair follicles, Priovant Therapeutics, Inc. is initiating NCT07532603, a Phase 2/3 study of brepocitinib in adults with lichen planopilaris. This trial seeks 342 participants to assess the safety and effectiveness of an oral medication.
• The University of Oregon is leading NCT07529327, a study aimed at preventing language delays and disorders among children of caregivers with substance use disorders. This important research, involving 244 participants, will test community groups and individualized services to improve early language development.
• The OHSU Knight Cancer Institute is sponsoring NCT07511504, a Phase 2 trial for unresectable and locally-advanced hepatocellular carcinoma. This study combines Y-90 radioembolization with durvalumab, tremelimumab, and zanzalintinib, enrolling 40 participants to explore a multifaceted treatment approach.
• Legacy Health System is conducting NCT07506876, a Phase 2 study investigating concurrent neoadjuvant chemo/endocrine therapy in HER2+ breast cancer. This trial, designed for 30 participants, aims to see if adding endocrine therapy to standard chemotherapy and HER2-directed therapy improves outcomes.

The new trials this month are addressing a diverse set of conditions, including:

• Breast Cancer - Infiltrating Ductal Carcinoma
• HER-2 Positive Breast Cancer
• Language Delay
• Language Development
• Language Disorders in Children
• Lichen Planopilaris
• Locally Advanced Hepatocellular Carcinoma
• Neonates or Premature Babies
• NICU Infants
• Obesity

These new studies primarily involve drug interventions, with 5 new drug trials, alongside behavioral interventions, biological treatments, and other types of research.

Oregon's Research Landscape: Where to Find Opportunities

Oregon currently hosts a robust research environment, with 1,185 clinical trials actively recruiting across 38 cities and 532 research sites. This widespread network ensures that opportunities are available across the state, not just in major metropolitan areas.

This month's new trials show a strong concentration in the Portland area, with 8 of the 9 new studies opening there. However, other cities also saw new research initiatives, including Eugene, Gresham, and Tualatin, each with 1 new trial. This distribution reflects both the concentration of major research institutions in Portland and the growing reach of clinical research into other communities.

Who Can Participate? Eligibility and Healthy Volunteer Opportunities

Clinical trials are designed to include a wide range of participants, and this month's new studies in Oregon are no exception. Of the 9 new trials, 9 are open to older adults, ensuring that senior populations have ample opportunities to contribute to medical advancements. Additionally, 1 new trial includes children, and 1 is specifically designed for male participants.

While none of the 9 newly opened trials are seeking healthy volunteers this month, there are still significant opportunities statewide. A total of 108 clinical trials across Oregon are currently recruiting healthy participants, providing numerous avenues for individuals without specific medical conditions to support medical research. Remember, 7 of these healthy volunteer trials are closing soon, so prompt action is encouraged.

Academic institutions and industry sponsors are both driving innovation in Oregon. The OHSU Knight Cancer Institute, Legacy Health System, and the University of Oregon are key academic contributors, while major industry players like Incyte Corporation, Novo Nordisk A/S, and Priovant Therapeutics, Inc. are bringing significant drug development trials to the state.

As we move through April, the focus will continue to be on enrolling participants in these vital studies, advancing our understanding of various health conditions and bringing new treatments closer to those who need them.